Life sciences accelerator creates seventy new companies since inception

MediCity Glasgow, a multi-agency supported incubator & accelerator project, has helped create seventy new life sciences and med-tech companies in the last five years, according to new figures.

The project’s success includes 201 new jobs generated within Scotland’s thriving life sciences sector, coupled with over £26 million raised in private investment, against a project goal of just £5 million at its outset.

The MediCity approach focuses on coaching evidence-based entrepreneurship, allowing scientists to test hypotheses about the commercial viability of their ideas without the need for significant investment.

It also develops the skills and mindset required to accelerate the commercialisation of scientific research from lab to market.

“The MediCity project and its accelerator programme has provided a supportive and exciting environment for companies to commercialise opportunities in MedTech, HealthTech, Digital Health, Healthcare and Wellness since its launch in 2015,” said Colin Roberts, Venture Development Director of BioCity Group, pioneers of the MediCity project.

“The success of the new companies in raising significant private investment funding and creating new high value jobs across Scotland demonstrates the value of its collaborative approach which has far exceeded many of its original targets.

“The outcomes have been achieved with relatively modest public sector co-funding, representing a significant return on investment for the project stakeholders.

“MediCity Glasgow operates holistically, supporting entrepreneurs at every stage, whether they have the mere spark of an idea or are further along the path to commercialisation.

“By applying scientific rigour to the business process, residents are taught to revise, adjust and fine tune their approach to commercialisation as they would when driving forward the science behind their product.

“Continued and sustained investment in the commercialisation of life sciences and health technology research is essential to both economic recovery in Scotland and the continued fight against COVID-19.

“If continued, the project can scale its impact on the sector even further, significantly building on Scotland’s established expertise in life sciences and complementing a number of new infrastructure projects planned across Scotland. These will require a significant pool of early stage companies to ensure longer term growth targets are met during and beyond the pandemic.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics

FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, have signed an agreement...

Beckman Coulter launch SARS-CoV-2 IgM antibody test in countries accepting CE Mark

Beckman Coulter, a clinical diagnostics leader, has announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark. The...

95% efficiency for Pfizer & BioNTech’s mRNA-based COVID vaccine candidate

Pfizer and BioNTech’s mRNA-based COVID-19 vaccine candidate – BNT162b2 – has achieved an efficiency rate of 95% after hitting all primary endpoints in a...

BMS completes $13bn MyoKardia acquisition

Bristol Myers Squibb (BMS) has completed its $13.1 billion acquisition of MyoKardia. “We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb,” said BMS...

Samsung Biologics breaks ground on ‘world’s largest’ biopharma manufacturing facility

Samsung Biologics has officially begun construction of its Plant 4 in Incheon, South Korea. Dubbed the “Super Plant”, the new, multi-story 238,000-square-meter construction will be...

Related news

Regeneron’s antibody cocktail granted Emergency Use Authorisation

The FDA has granted Emergency Use Authorisation (EUA) to Regeneron’s antibody cocktail for COVID-19. The cocktail combines casirivimab and imdevimab administered together is the first...

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics

FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, have signed an agreement...

Beckman Coulter launch SARS-CoV-2 IgM antibody test in countries accepting CE Mark

Beckman Coulter, a clinical diagnostics leader, has announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark. The...

95% efficiency for Pfizer & BioNTech’s mRNA-based COVID vaccine candidate

Pfizer and BioNTech’s mRNA-based COVID-19 vaccine candidate – BNT162b2 – has achieved an efficiency rate of 95% after hitting all primary endpoints in a...